Aktieanalys

Curasight Q2: Strategic progress - Redeye

{newsItem.title}

Redeye Publicerad: 26 Aug 2024 12:50

Redeye updates its view of Curasight following the Q2 report and recent events in the company, including an announced financing solution and progress with uTRACE in prostate cancer.

Länk till analysen i sin helhet: https://www.redeye.se/research/1034810/curasight-q2-strategic-progress?utm_source=finwire&utm_medium=RSS

Nyheter om Curasight

Läses av andra just nu

Om aktien Curasight

Senaste nytt